In today’s briefing:
- Quiddity Leaderboard HSCEI Dec26: Two ADDs/DELs Likely
- Guotai Junan (1788 HK): A Closer Look At The Shareholder Register
- Alibaba (9988 HK): Synthetic Expert Call Transcript (10 Sep 2026)
- Quiddity Leaderboard HSTECH Dec26: OLD Vs NEW Methodology; Mega Flows Possible
- Aequitas: Genscript Biotech Placement – Earnings-Led Inflection; Re-Rating May Limit Upside
- Quiddity Leaderboard HSIII Dec26/Mar27: Two Changes Likely in Mar27; One More Close to the Border
- Swire Pacific (19 HK): Synthetic Expert Call Transcript (10 Sep 2026)
- Changhong Jiahua (3991 HK): The Upcoming Long Stop Date Sets the Pretext for a Deal Break
- Wasion (3393): Undervalued
- JD.com, Inc. Class A – JD.com’s Joybuy Expansion — Could Europe Become the Next Big Growth Lever?
Quiddity Leaderboard HSCEI Dec26: Two ADDs/DELs Likely
- The HSCEI serves as a benchmark to reflect the overall performance of the top 50 “Mainland China” securities listed in Hong Kong.
- In this insight, we take a look at the rankings of potential ADDs and potential DELs for the December 2026 index rebal event.
- At present, we see two changes based on the latest data but the rankings can change until 30th September 2026.
Guotai Junan (1788 HK): A Closer Look At The Shareholder Register
- On the 7th July Guotai Haitong Securities (601211 CH) pitched a pre-conditional (SASAC/NDRC) Scheme for Guotai Junan (1788 HK) at HK$3/share, a 44.2% premium to last closes. Terms declared final.
- The pre-con long stop date is the 31st October – uncommonly nimble. This could (should) be wrapped up before year-end. Clean deal.
- A perusal of the s329 investigative reports provides a clearer picture on who holds what. Not that I expect the vote to be a cause for concern.
Alibaba (9988 HK): Synthetic Expert Call Transcript (10 Sep 2026)
- Alibaba’s recent HK$80 billion (US$10.2 billion) equity placement was a direct response to offshore liquidity pressure. This funding strategy bypasses the 10% mainland withholding tax and State Administration of Foreign Exchange (SAFE) approval frictions required to transfer onshore e-commerce profits to the offshore Cayman holding company to support capital projects and existing buybacks.
- The cancellation of Cloud and Cainiao spin-offs reflects a strategic reality rather than just regulatory retreat. Cloud has been repurposed as a capital-intensive “full-stack AI factory” that requires immense, ongoing cash subsidies from core commerce, while Cainiao’s full integration is structurally necessary to compete with Temu and Shein in international logistics.
- Heavy AI investments have pushed quarterly Capex to RMB 67.7 billion, leading to a negative free cash flow of RMB 44.6 billion in the June 2026 quarter. This aggressive infrastructure spending carries highly ambitious 2-to-3-year payback targets that remain vulnerable to China’s ongoing domestic cloud price wars and a shifting margin pool where merchant take-rates are structurally squeezed.
Disclaimer: The following transcripts are synthetic, AI-generated on demand, and compiled exclusively from public data sources; no real-word experts were actually interviewed. This content is designed to highlight potential market mispricings, explore compelling lines of inquiry, and suggest strategic questions rather than present verified facts. All specific financial metrics and data points, including market shares, TAM, margins, and growth rates, are AI-estimated approximations. They may be inaccurate and must be independently verified.
Quiddity Leaderboard HSTECH Dec26: OLD Vs NEW Methodology; Mega Flows Possible
- The current HSTECH Index tracks the performance of the top 30 technology companies listed in Hong Kong that have high business exposure to certain technology themes.
- A new methodology has been proposed and if implemented, index composition could change drastically in the next index rebal event.
- There could be at least 20 changes to the index as the new methodology aims to increase index member count from 30 to 50 in December 2026.
Aequitas: Genscript Biotech Placement – Earnings-Led Inflection; Re-Rating May Limit Upside
- GenScript Biotech (1548 HK) is looking to raise up to US$300m from a primary placement. Proceeds are to be used for capacity expansion and platform infrastructure purposes.
- Genscript Biotech is a global life-science platform spanning research tools and services, biologics CDMO (ProBio) and industrial synthetic biology, with additional exposure to cell therapy through Legend Biotech.
- In this note, we will talk about the placement and run the deal through our ECM framework.
Quiddity Leaderboard HSIII Dec26/Mar27: Two Changes Likely in Mar27; One More Close to the Border
- The Hang Seng Internet & IT (HSIII) index represents the top 30 Hong Kong-listed stocks related to internet and information technology businesses.
- We expect no index changes in December 2026 but we see capping flows of ~US$112mn one-way.
- We expect at least two ADDs/DELs in the next index review which will take place in March 2027.
Swire Pacific (19 HK): Synthetic Expert Call Transcript (10 Sep 2026)
- Cathay Share Placement and Bond Buyback: Swire Pacific’s September 2, 2026 accelerated exchange trade—selling a 5.96% stake in Cathay Pacific (362.65 million shares) at HK$13.20 to fund the repurchase of HK$4.69 billion in zero-coupon exchangeable bonds due 2027—strategically removes a major dilution overhang. While it trims Swire’s Cathay stake to 39.15%, it locks in a HK$1.12 billion gain on the placement and leaves Swire’s management control fully intact.
- Dual-Class B-Share Discount Anomalies: The A-to-B share premium is currently at a 24-year high (with B-shares trading at a ~28% discount to their theoretical 1/5th economic value of the A-shares). Despite this massive discrepancy, a share consolidation is structurally blocked by parent company John Swire & Sons, who hold 74.83% of B-shares to maintain 70.97% voting control over the listed group at a cheaper economic cost.
- Parent-Subsidiary Misalignment and KPI Anchoring: Executive compensation and alignment at Swire Pacific are heavily biased toward the private UK parent, John Swire & Sons, through a long-standing Services Agreement. Senior leadership are JSS secondees whose long-term incentives are tied to the private parent’s global returns rather than public market share performance, explaining their high tolerance for a persistent 30% to 40% NAV discount.
Disclaimer: The following transcripts are synthetic, AI-generated on demand, and compiled exclusively from public data sources; no real-word experts were actually interviewed. This content is designed to highlight potential market mispricings, explore compelling lines of inquiry, and suggest strategic questions rather than present verified facts. All specific financial metrics and data points, including market shares, TAM, margins, and growth rates, are AI-estimated approximations. They may be inaccurate and must be independently verified.
Changhong Jiahua (3991 HK): The Upcoming Long Stop Date Sets the Pretext for a Deal Break
- Almost a year in, Changhong Group has yet to secure the regulatory approvals for its HK$1.223 scheme offer for Changhong Jiahua (3991 HK).
- The offer will be effectively blocked, not by a Sichuan NDRC/Commerce rejection with stated reasons, but by the approval process failing to conclude by the 20 September long stop date.
- On a deal break, I expect little-to-no downside due to improving fundamentals, significant peer re-rating and significant discount to the undisturbed price.
Wasion (3393): Undervalued
- Wasion (3393 HK) share price remains depressed, even though revenue and orders hit record highs, but margins are not expanding.
- AI and data center-related revenue +153% YoY to RMB 1.89 billion. The company is now an AI-related name; hence, higher valuation?
- The share buyback should pull some confidence back into the share price but if they cancel the shares, then it is even a stronger signal.
JD.com, Inc. Class A – JD.com’s Joybuy Expansion — Could Europe Become the Next Big Growth Lever?
- JD.com’s second quarter of 2026 results showed a steady operational performance amid challenging macroeconomic and industry conditions, delivering a mix of positives and areas for cautious observation.
- Revenues declined slightly by 2.9% year-over-year to RMB 346 billion, primarily due to headwinds in the electronics and home appliances categories.
- This segment faced pressure from a high comparison base linked to last year’s trade-in program and upstream raw material cost increases.
💡 Before it’s here, it’s on Smartkarma
Sign Up for Free
The Smartkarma Preview Pass is your entry to the Independent Investment Research Network
- ✓ Unlimited Research Summaries
- ✓ Personalised Alerts
- ✓ Custom Watchlists
- ✓ Company Data and News
- ✓ Events & Webinars
